Taysha Gene Therapies (TSHA) Tops Q1 EPS by 8c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($0.28), $0.08 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $4.71 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
• Sun Communities names Ileana McAlary as general counsel and EVP
• MP Materials seen largely insulated after China export-control move